

Tuesday, November 21, 2023



Volume 42 No. 11

NOTICE – Items in this issue will be listed online weekly and printed monthly.

**BON NATURAL LIFE LTD
Annual Report**

**Standardized Income Statement, Years Ended Sept. 30
(\$000):**

	2022	2021	2020 (revised)
Revenue	29,909	25,495	18,220
Direct Expenses	20,485	18,383	13,018
Gross Profit	9,424	7,112	5,202
SG&A	2,459	1,462	1,529
R&D (OpEx)	425	249	205
Other OpEx	0	0	0
Indirect Expenses	2,883	1,711	1,734
Total Operating Expenses	23,368	20,094	14,752
Operating Income	6,540	5,401	3,468
Non-Op Net Interest Income	(445)	(414)	(328)
Non-Op For Curr Gains	19	(45)	(0)
Non-Op Gains	20
Other Non-Op	1,396	489	495
Non-Op Income	969	30	186
EBT Continuing	7,509	5,430	3,655
Taxation (current)	1,248	792	564
Taxation (deferred)	19	29	(8)
Taxation	1,267	821	556
Min Ints.	5	19	72
Extraord	0	0	0
Acc Changes	0	0	0
Net Income	6,237	4,591	3,027
Pref Divs & Similar	0	0	0
Net Income to Common	6,237	4,591	3,027
EPS - Basic - Cont	0.75	0.69	0.58
EPS - Primary	0.75	0.69	0.58
EPS - Diluted - Cont	0.74	0.68	0.58
EPS - Diluted	0.74	0.68	0.58
Shares (primary)	8,361	6,616	5,211
Shares (diluted)	8,396	6,706	5,211

Standardized Balance Sheet, Years Ended Sept. 30 (\$000):

	2022	2021	2020
Cash	841	1,904	3,607
Cash & Equivalents	841	3,607	841
Cash, Equivs & STI	841	3,607	6,784
Receivables	6,784	6,153	677
Raw Materials	677	555	1,052
Finished Goods	1,052	1,189	(14)
Inventories - Other	(14)	(296)	1,722
Inventories	1,722	1,596	4,092
Prepayments (ST)	4,092	4,094	1,278
Other Current Assets	1,278	1,099	14,717
Current Assets	14,717	16,550	23,311
Gross PPE	23,311	20,881	1,686
Accumulated Depreciation	1,686	1,652	21,624
Net PPE	21,624	19,229	366
Intangibles	366	411	3
Deferred LT Asset Charges	3	22	547
Other LT Assets	547	201	22,540
LT Assets	22,540	19,863	37,257
Total Assets	37,257	36,413	215
Accounts Payable	215	380	664
Accrued Exps	664	3,361	878
Accounts Payable & Accrued Expenses	878	3,741	3,741

	2022	2021	2020
Current Debt	4,561	489	489
Current Capital Lease Obligations	26	161	26
Current Debt and Capital Leases	4,587	651	515
Related Parties (ST Liab)	73	245	1,109
Other Current Liabilities	1,109	2,892	6,647
Current Liabilities	6,647	7,529	190
Long-Term Obligations	190	2,202	327
Other LT Liabilities	327	147	530
Minorities (BS)	530	528	1,048
LT Liabilities	1,048	2,877	7,695
Total Liabilities	7,695	10,406	29,562
Net Assets	29,562	26,007	1
Common Share Capital	1	1	15,711
Share Premium	15,711	15,540	14,677
Retained Earnings	14,677	9,193	(2,631)
Accum Other Comp Inc	(2,631)	222	1,804
Other Equity	1,804	1,051	29,562
Shareholders' Equity	29,562	26,007	37,257
Total Liabilities & Shareholders' Equity	37,257	36,413	8,069
Net Current Assets	8,069	9,021	30,610
Total Assets Less Current Liabilities	30,610	28,884	8,396
Shares Outstanding	8,396	8,330	

Recent Dividends:

1. Bon Natural Life Ltd ordinary.
No dividends paid.

Annual Dividends:

1. Bon Natural Life Ltd ordinary.
No dividends paid.

FANHUA INC

Annual Report

**Standardized Income Statement, Years Ended Dec. 31
(\$000):**

	2022	2021	2020 (revised)
Sales	2,781,614	3,271,114	3,268,145
Revenue	2,781,614	3,271,114	3,268,145
Direct Expenses	1,795,603	2,115,167	2,213,865
Gross Profit	986,011	1,155,947	1,054,280
Other OpEx	0	0	752,094
Indirect Expenses	817,336	854,042	752,094
Total Operating Expenses	2,612,939	2,969,209	2,965,959
Operating Income	168,675	301,905	302,186
Non-Op Net Interest Income	13,674	2,971	13,420
Non-Op Gains	17,809	32,898	34,789
Other Non-Op	(3,823)	33,314	11,907
Non-Op Income	27,660	69,183	60,116
EBT Continuing	196,335	371,088	362,302
Taxation	41,016	90,574	83,387
Min Ints.	(14,549)	8,952	7,923
Equity Earns	(69,596)	(20,573)	(2,738)
Extraord	0	0	0
Acc Changes	0	0	0
Net Income	100,272	250,989	268,254
Pref Divs & Similar	0	0	0
Net Income to Common	100,272	250,989	268,254
Dividends Per Share	0.92	4.39	7.11
EPS - Basic - Cont	0.09	0.23	0.25
EPS - Primary	0.09	0.23	0.25
EPS - Diluted			

	2022	2021	2020
Cont	0.09	0.23	0.25
EPS - Diluted	0.09	0.23	0.25
Shares (primary)	1,074,196	1,073,892	1,073,892
Shares (diluted)	1,074,458	1,074,291	1,074,291

Standardized Balance Sheet, Years Ended Dec. 31 (\$000):

	2022	2021	2020
Cash & Equivalents	567,525	564,624	347,754
Short Term Investments	347,754	870,682	915,279
Cash, Equivs & STI	915,279	1,435,306	898,603
Receivables	898,603	714,512	479,692
Other Current Assets	479,692	116,250	2,293,574
Current Assets	2,293,574	2,266,068	290,404
Gross PPE	290,404	210,115	191,945
Accumulated Depreciation	191,945	163,315	98,459
Net PPE	98,459	46,800	4,035
LT Investments	4,035	335,808	109,997
Goodwill	109,997	109,869	109,997
Intangibles	109,997	109,869	20,402
Deferred LT Asset Charges	20,402	18,728	563,049
Other LT Assets	563,049	464,845	795,942
LT Assets	795,942	976,050	3,089,516
Total Assets	3,089,516	3,242,118	362,352
Accounts Payable	362,352	335,721	170,711
Accrued Exps	170,711	153,509	723,969
Accounts Payable & Accrued Expenses	723,969	691,441	35,679
Current Debt	35,679	...	35,679
Current Debt and Capital Leases	35,679	...	192,328
Other Current Liabilities	192,328	217,234	951,976
Current Liabilities	951,976	908,675	102,455
Deferred LT Liability Charges	102,455	73,716	303,754
Other LT Liabilities	303,754	299,365	107,928
Minorities (BS)	107,928	122,477	514,137
LT Liabilities	514,137	495,558	1,466,113
Total Liabilities	1,466,113	1,404,233	1,623,403
Net Assets	1,623,403	1,837,885	8,091
Common Share Capital	8,091	8,089	461
Share Premium	461	...	1,087,984
Retained Earnings	1,087,984	1,311,715	(32,643)
Accum Other Comp Inc	(32,643)	(39,140)	10
Treasury Stock	10	...	559,520
Other Equity	559,520	557,221	1,623,403
Shareholders' Equity	1,623,403	1,837,885	3,089,516
Total Liabilities & Shareholders' Equity	3,089,516	3,242,118	1,341,598
Net Current Assets	1,341,598	1,357,393	2,137,540
Total Assets Less Current Liabilities	2,137,540	2,333,443	1,072,842
Shares Outstanding	1,072,842	1,073,892	

Recent Dividends:

1. Fanhua Inc ordinary.

ExDate	Amt	Declared	Record	Payable
04/02/2020	0.01		04/16/2020	
06/10/2020	0.01		06/24/2020	
09/08/2020	0.01		09/22/2020	
12/09/2020	0.01		12/23/2020	
03/31/2021	0.01		04/15/2021	
06/11/2021	0.01		06/25/2021	
09/13/2021	0.01		09/23/2021	
12/08/2021	0.01		12/22/2021	
04/12/2022	0.01		04/26/2022	

2. Fanhua Inc American Depositary Shares.

ExDate	Amt	Declared	Record	Payable
04/01/2020	0.29		04/02/2020	04/16/2020
06/09/2020	0.24		06/10/2020	06/24/2020
09/04/2020	0.24		09/08/2020	09/22/2020
12/08/2020	0.24		12/09/2020	12/23/2020
03/30/2021	0.24		03/31/2021	04/15/2021
06/10/2021	0.14		06/11/2021	06/25/2021
09/10/2021	0.14		09/13/2021	09/23/2021
12/07/2021	0.14		12/08/2021	12/22/2021
04/11/2022	0.14		04/12/2022	04/26/2022
06/08/2022	0.00		06/09/2022	06/28/2022

Annual Dividends:**1. Fanhua Inc ordinary.**

2020.....0.05	2021.....0.04	2022.....0.01
---------------	---------------	---------------

2. Fanhua Inc American Depositary Shares.

2020.....1.03	2021.....0.68	2022.....0.15
---------------	---------------	---------------

HELIX BIOPHARMA CORP**Annual Report****Standardized Income Statement, Years Ended Jul. 31 (Can\$000):**

	2023	2022	2021
SG&A	185	443	2,585
D&A (OpEx)	3
R&D (OpEx)	5,281	4,544	5,880
Other OpEx	860	1,053	663
Indirect Expenses	6,326	6,040	9,131
Total Operating Expenses	6,326	6,040	9,131
Non-Op For Curr Gains	(2)	(9)	52
Other Non-Op	38	(514)	(495)
Non-Op Income	36	(523)	(443)
EBT Continuing	(6,290)	(6,563)	(9,574)
Disc Ops	1,536
Net Income	(6,290)	(6,563)	(8,038)
EPS - Basic - Cont	(0.03)	(0.04)	(0.06)
EPS - Primary	(0.03)	(0.04)	(0.06)
EPS -Diluted - Cont	(0.03)	(0.04)	(0.06)
EPS - Diluted	(0.03)	(0.04)	(0.06)
Shares (primary)	193,229	149,487	137,889
Shares (diluted)	193,229	149,487	137,889

Standardized Balance Sheet, Years Ended Jul. 31 (Can\$000):

	2023	2022	2021
Cash	808	3,252	808
Cash & Equivalents	808	3,252	808
Cash, Equivs & STI	808	3,252	808
Receivables	62	279	126
Prepayments (ST)	126	164	0
Other Current Assets	0	0	0
Current Assets	996	3,695	1,823
Gross PPE	1,823	1,813	(1,790)
Accumulated Depreciation	(1,790)	(1,778)	33
Net PPE	33	36	0
Other LT Assets	0	0	33
LT Assets	33	36	1,029
Total Assets	1,029	3,730	493
Accounts Payable	493	599	383
Accrued Exps	383	345	876
Accounts Payable & Accrued Expenses	876	944	2,468
Current Debt	2,468	...
Current Debt and Capital Leases	2,468	998
Other Current Liabilities	998	(1)	1,874
Current Liabilities	1,874	3,411	0
Long-Term Obligations	0	0	1,874
Total Liabilities	1,874	3,411	(845)
Net Assets	(845)	319	152,068
Common Share Capital	152,068	147,511	44,137
Share Premium	44,137	37,590	(201,407)
Retained Earnings	(201,407)	(195,117)	4,358
Other Equity	4,358	10,335	...

Shareholders' Equity	(844)	319
Total Liabilities & Stockholders' Equity	1,029	3,730
Net Current Assets	(878)	284
Total Assets Less Current Liabilities	(845)	319
Shares Outstanding	200,019	171,795

Recent Dividends:

1. Helix BioPharma Corp common.
No dividends paid.

Annual Dividends:

1. Helix BioPharma Corp common.
No dividends paid.

HELIX BIOPHARMA CORP**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Clearhouse LLP, as it appeared in Co.'s 2023 Annual Report: "Opinion We have audited the financial statements of Helix Biopharma Corp. (the Company), which comprise the statements of financial position as at July 31, 2023 and the statements of loss and comprehensive loss, statements of changes in equity and statements of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies. In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as at July 31, 2023 and its financial performance and its cash flows for the year then ended, in accordance with International Financial Reporting Standards.. Material Uncertainty Related to Going Concern We draw your attention to Note 1 in the financial statements, which indicates that the Company incurred a comprehensive loss of \$6,290,072 during the year ended July 31, 2023. As stated in Note 1, these events or conditions, along with other matters as set forth in Note 1, indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter."

HUIZE HOLDING LTD**Annual Report****Standardized Income Statement, Years Ended Dec. 31 (Y000):**

	2022	2021	2020
Revenue	1,157,908	2,245,016	1,220,222
General & Admin Expenses	154,715	197,619	150,207
Other Insurance Expense	1,034,733	2,157,774	1,086,778
Benefits & Expenses	1,189,448	2,355,393	1,236,985
EBT Continuing	(31,540)	(110,377)	(16,763)
Taxation	1,768
Min Ints	(2,553)	(51)	...
Equity Earnings	(2,200)	2,660	...
Extraord	0	0	0
Acc Changes	0	0	0
Net Income	(31,187)	(107,666)	(18,292)
Pref Divs & Similar	0	0	(3,200)
Net Income to Common	(31,187)	(107,666)	(21,492)
EPS - Basic - Cont	(0.03)	(0.11)	(0.02)
EPS - Primary	(0.03)	(0.11)	(0.02)
EPS -Diluted - Cont	(0.03)	(0.11)	(0.02)
EPS - Diluted	(0.03)	(0.11)	(0.02)
Shares (primary)	1,021,959	1,021,861	963,818
Shares (diluted)	1,021,959	1,021,861	963,818

Standardized Balance Sheet, Years Ended Dec. 31 (Y000):

	2022	2021	2020
Cash & Equivalents	277,168	381,158	68,341
Gross PPE	68,341	71,477	29,823
Accumulated Depreciation	29,823	23,016	38,518
Net PPE	38,518	48,461	461
Goodwill	461	461	53,498
Intangibles Excl Goodwill	53,498	21,626	53,959
Intangibles	53,959	22,087	...
Related Parties (Total Asset)	489	128	719,480
Other Assets	719,480	1,405,620	...

Total Assets	1,089,614	1,857,454
Accrued Exps	43,938	93,451
Minorities (BS)	1,146	849
Related Parties (Total Liability)	495	11,875
Debt & Lease Obligations	20,000
Other Liabilities	703,156	1,371,215
Total Liabilities	748,735	1,497,390
Net Assets	340,879	360,064
Common Share Capital	72	72
Share Premium	904,935	896,772
Retained Earnings	(531,127)	(499,940)
Accum Other Comp Inc	(17,695)	(27,295)
Treasury Stock	15,306	9,545
Other Equity	0	0
Shareholders' Equity	340,879	360,064
Total Liabilities & Stockholders' Equity	1,089,614	1,857,454
Shares Outstanding	1,023,660	1,036,758

Recent Dividends:

1. Huize Holding Ltd class A common.

No dividends paid.

2. Huize Holding Ltd series B+ redeemable preferred.

No dividends paid.

3. Huize Holding Ltd series B redeemable preferred.

No dividends paid.

4. Huize Holding Ltd common.

No dividends paid.

5. Huize Holding Ltd class B common.

No dividends paid.

6. Huize Holding Ltd series A redeemable preferred.

No dividends paid.

7. Huize Holding Ltd series B++ redeemable preferred.

No dividends paid.

8. Huize Holding Ltd American Depositary Receipts.

No dividends paid.

Annual Dividends:

1. Huize Holding Ltd class A common.

No dividends paid.

2. Huize Holding Ltd series B+ redeemable preferred.

No dividends paid.

3. Huize Holding Ltd series B redeemable preferred.

No dividends paid.

4. Huize Holding Ltd common.

No dividends paid.

5. Huize Holding Ltd class B common.

No dividends paid.

6. Huize Holding Ltd series A redeemable preferred.

No dividends paid.

7. Huize Holding Ltd series B++ redeemable preferred.

No dividends paid.

8. Huize Holding Ltd American Depositary Receipts.

No dividends paid.

INMED PHARMACEUTICALS INC**Annual Report****Standardized Income Statement, Years Ended Jun. 30 (\$000):**

	2023	2022	2021
Sales	4,136	1,089	...
Revenue	4,136	1,089	...
Direct Expenses	2,733	546	...
Gross Profit	1,403	544	...
SG&A	5,848	6,867	4,479
D&A (OpEx)	202	186	121
R&D (OpEx)	3,732	7,283	5,338
RR&I	3,473	...
Other OpEx	0	0	0
Indirect Expenses	9,782	17,808	9,938
Total Operating Expenses	12,514	18,354	9,938
Operating Income	(8,379)	(17,264)	...
Non-Op Net Interest Income	492	96	16
Non-Op For Curr Gains	(48)	(118)	(163)
Non-Op Gains	243
Other Non-Op	0	(1,314)	(360)
Non-Op Income	444	(1,336)	(265)
EBT Continuing	(7,935)	(18,600)	(10,203)
Taxation	13
Extraord	0	0	0

Acc Changes	0	0	0	Income	492	96	16	Total Operating			
Net Income	(7,948)	(18,600)	(10,203)	Non-Op For Curr				Expenses	16,080	11,070	596
Pref Divs &				Gains	(48)	(118)	(163)	Non-Op For Curr			
Similar	0	0	0	Non-Op Gains	243	Gains	996	410	(0)
Net Income to				Other Non-Op	0	(1,314)	(360)	Other Non-Op	(294)	1,214	43
Common	(7,948)	(18,600)	(10,203)	Non-Op Income	444	(1,336)	(265)	Non-Op Income	702	1,623	43
EPS - Basic - Cont	(3.25)	(33.17)	(37.96)	EBT Continuing	(7,935)	(18,600)	(10,203)	EBT Continuing	(15,378)	(9,446)	(552)
EPS - Primary	(3.25)	(33.17)	(37.96)	Taxation	13	Net Income	(15,378)	(9,446)	(552)
EPS -Diluted -				Extraord	0	0	0	EPS - Basic - Cont	(0.85)	(0.60)	(0.04)
Cont	(3.25)	(33.17)	(37.96)	Acc Changes	0	0	0	EPS - Primary	(0.85)	(0.60)	(0.04)
EPS - Diluted	(3.25)	(33.17)	(37.96)	Net Income	(7,948)	(18,600)	(10,203)	EPS - Diluted -			
Shares (primary)	2,448	561	269	Pref Divs &				Cont	(0.85)	(0.60)	(0.04)
Shares (diluted)	2,448	561	269	Similar	0	0	0	EPS - Diluted	(0.85)	(0.60)	(0.04)

Standardized Balance Sheet, Years Ended Jun. 30 (\$000):

	2023	2022
Cash & Equivalents	8,913	6,177
Short Term Investments	44	45
Cash, Equivs & STI	8,957	6,222
Receivables	260	88
Inventories - Other	1,616	2,491
Inventories	1,616	2,491
Other Current Assets	498	797
Current Assets	11,332	9,598
Gross PPE	1,649	1,421
Accumulated Depreciation	925	516
Net PPE	723	904
Intangibles Excl Goodwill	1,946	2,109
Intangibles	1,946	2,109
Other LT Assets	105	177
LT Assets	2,775	3,190
Total Assets	14,106	12,788
Accounts Payable	544	1,166
Accrued Exps	1,065	1,249
Accounts Payable &		
Accrued Expenses	1,609	2,915
Other Current Liabilities	392	404
Current Liabilities	2,001	3,320
Other LT Liabilities	16	389
Minorities (BS)	0	0
LT Liabilities	16	389
Total Liabilities	2,017	3,709
Net Assets	12,090	9,079
Common Share Capital	77,620	70,718
Share Premium	35,741	31,684
Retained Earnings	(101,400)	(93,453)
Accum Other Comp Inc	129	129
Other Equity	0	0
Shareholders' Equity	12,090	9,079
Total Liabilities &		
Stockholders' Equity	14,106	12,788
Net Current Assets	9,331	6,278
Total Assets Less Current		
Liabilities	12,106	9,468
Shares Outstanding	3,328	651

Recent Dividends:**1. InMed Pharmaceuticals Inc common.**

No dividends paid.

Annual Dividends:**1. InMed Pharmaceuticals Inc common.**

No dividends paid.

INMED PHARMACEUTICALS INC**Annual Report****Standardized Income Statement, Years Ended Jun. 30 (\$000):**

	2023	2022	2021
			(revised)
Sales	4,136	1,089	...
Revenue	4,136	1,089	...
Direct Expenses	2,733	546	...
Gross Profit	1,403	544	...
SG&A	5,848	6,867	4,479
D&A (OpEx)	202	186	121
R&D (OpEx)	3,732	7,283	5,338
RR&I	...	3,473	...
Other OpEx	0	0	0
Indirect Expenses	9,782	17,808	9,938
Total Operating			
Expenses	12,514	18,354	9,938
Operating Income	(8,379)	(17,264)	...
Non-Op Net Interest			

Standardized Balance Sheet, Years Ended Jun. 30 (\$000):

	2023	2022
Cash & Equivalents	8,913	6,177
Short Term Investments	44	45
Cash, Equivs & STI	8,957	6,222
Receivables	260	88
Inventories - Other	1,616	2,491
Inventories	1,616	2,491
Other Current Assets	498	797
Current Assets	11,332	9,598
Gross PPE	1,649	1,421
Accumulated Depreciation	925	516
Net PPE	723	904
Intangibles Excl Goodwill	1,946	2,109
Intangibles	1,946	2,109
Other LT Assets	105	177
LT Assets	2,775	3,190
Total Assets	14,106	12,788
Accounts Payable	544	1,166
Accrued Exps	1,065	1,249
Accounts Payable &		
Accrued Expenses	1,609	2,915
Other Current Liabilities	392	404
Current Liabilities	2,001	3,320
Other LT Liabilities	16	389
Minorities (BS)	0	0
LT Liabilities	16	389
Total Liabilities	2,017	3,709
Net Assets	12,090	9,079
Common Share Capital	77,620	70,718
Share Premium	35,741	31,684
Retained Earnings	(101,400)	(93,453)
Accum Other Comp Inc	129	129
Other Equity	0	0
Shareholders' Equity	12,090	9,079
Total Liabilities &		
Stockholders' Equity	14,106	12,788
Net Current Assets	9,331	6,278
Total Assets Less Current		
Liabilities	12,106	9,468
Shares Outstanding	3,328	651

Recent Dividends:**1. InMed Pharmaceuticals Inc common.**

No dividends paid.

Annual Dividends:**1. InMed Pharmaceuticals Inc common.**

No dividends paid.

SNOW LAKE RESOURCES LTD**Annual Report****Standardized Income Statement, Years Ended Jun. 30 (Can\$000):**

	2023	2022	2021
			(revised)
SG&A	13,505	2,767	440
D&A (OpEx)	3	57	13
R&D (OpEx)	12	34	...
Other OpEx	2,560	8,213	142
Indirect Expenses	16,080	11,070	596

Standardized Balance Sheet, Years Ended Jun. 30 (Can\$000):

	2023	2022
Cash	3,841	23,792
Cash & Equivalents	3,841	23,792
Cash, Equivs & STI	3,841	23,792
Receivables	181	294
Related Parties (ST Asset)	10	10
Other Current Assets	884	932
Current Assets	4,916	25,029
LT Assets	21,503	12,078
Total Assets	26,419	37,107
Accounts Payable	722	568
Accrued Exps	302	614
Accounts Payable &		
Accrued Expenses	1,024	1,182
Current Debt	0	201
Current Capital Lease		
Obligations	30	...
Current Debt and Capital		
Leases	30	201
Related Parties (ST Liab)	87	110
Other Current Liabilities	1,922	287
Current Liabilities	3,063	1,781
Long-Term Obligations	0	0
Other LT Liabilities	31	...
LT Liabilities	31	...
Total Liabilities	3,094	1,781
Net Assets	23,325	35,326
Common Share Capital	40,571	39,734
Retained Earnings	(24,610)	(10,546)
Other Equity	7,365	6,138
Shareholders' Equity	23,325	35,326
Total Liabilities &		
Stockholders' Equity	26,419	37,107
Net Current Assets	1,853	23,248
Total Assets Less Current		
Liabilities	23,356	35,326
Shares Outstanding	18,186	17,925

Recent Dividends:**1. Snow Lake Resources Ltd common.**

No dividends paid.

Annual Dividends:**1. Snow Lake Resources Ltd common.**

No dividends paid.

SNOW LAKE RESOURCES LTD**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, DeVisser Gray LLP, as it appeared in Co.'s 2023 20-F: "Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated financial statements of Snow Lake Resources Ltd. (the "Company"), which comprise the consolidated statements of financial position as at June 30, 2023 and 2022 and the consolidated statements of loss and comprehensive loss, changes in shareholders' equity and cash flows for each of the years in the three year period ended June 30, 2023, and a summary of significant accounting policies and other explanatory information (collectively referred to as the "financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as

at June 30, 2023 and 2022 and its financial performance and its cash flows for each of the years in the three year period ended June 30, 2023, in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Going Concern Without modifying our opinion, we draw attention to Note 1 in the consolidated financial statements which indicates that there are material uncertainties that cast significant doubt about the going concern assumption. The Company has no current source of revenue, has incurred losses from inception and is dependent upon its ability to secure new sources of financing. These conditions, along with other matters as set forth in Note 1, indicate the existence of a material uncertainty that casts significant doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

TE CONNECTIVITY LTD Annual Report

Standardized Income Statement, Years Ended (\$000):			
	09/29/23	09/30/22	09/24/21 (revised)
Sales	16,034,000	16,281,000	14,923,000
Revenue	16,034,000	16,281,000	14,923,000
Direct Expenses	10,979,000	11,037,000	10,036,000
Gross Profit	5,055,000	5,244,000	4,887,000
SG&A	1,584,000	1,584,000	1,512,000
R&D (OpEx)	708,000	718,000	677,000
RR&I	293,000	182,000	239,000
Other OpEx	1,750,000	4,000	25,000
Indirect Expenses	2,751,000	2,488,000	2,453,000
Total Operating Expenses	13,730,000	13,525,000	12,489,000
Operating Income	2,304,000	2,756,000	2,434,000
Non-Op Net Interest Income	(20,000)	(51,000)	(39,000)
Other Non-Op	(16,000)	28,000	(17,000)
Non-Op Income	(36,000)	(23,000)	(56,000)
EBT Continuing	2,268,000	2,733,000	2,378,000
Taxation (current)	441,000	453,000	477,000
Taxation (deferred)	(77,000)	(147,000)	(354,000)
Taxation	364,000	306,000	123,000
Disc Ops	6,000	1,000	6,000
Extraord	0	0	0
Acc Changes	0	0	0
Net Income	1,910,000	2,428,000	2,261,000
Pref Divs & Similar	0	0	0
Net Income to Common	1,910,000	2,428,000	2,261,000
Dividends Per Share	2.30	2.12	1.96
EPS - Basic - Cont	6.04	7.51	6.83
EPS - Primary	6.06	7.52	6.85
EPS - Diluted - Cont	6.01	7.47	6.77
EPS - Diluted	6.03	7.47	6.79
Shares (primary)	315,000	323,000	330,000
Shares (diluted)	317,000	325,000	333,000

Standardized Balance Sheet, Years Ended (\$):

	09/29/23	09/30/22
Cash & Equivalents	1,661,000,000	1,088,000,000
Cash, Equivs & STI	1,661,000,000	1,088,000,000
Receivables	2,967,000,000	2,865,000,000
Raw Materials	367,000,000	390,000,000
WIP	1,185,000,000	1,066,000,000
Finished Goods	1,000,000,000	1,220,000,000
Inventories - Other	0	0
Inventories	2,552,000,000	2,676,000,000
Other Current Assets	712,000,000	639,000,000
Current Assets	7,892,000,000	7,268,000,000
Gross PPE	10,490,000,000	9,773,000,000
Accumulated Depreciation	6,736,000,000	6,206,000,000
Net PPE	3,754,000,000	3,567,000,000
Goodwill	5,463,000,000	5,258,000,000
Intangibles Excl Goodwill	1,175,000,000	1,288,000,000
Intangibles	6,638,000,000	6,546,000,000
Deferred LT Asset Charges	2,600,000,000	2,498,000,000
Other LT Assets	828,000,000	903,000,000
LT Assets	13,820,000,000	13,514,000,000
Total Assets	21,712,000,000	20,782,000,000
Accounts Payable	1,563,000,000	1,593,000,000
Accrued Exps	1,213,000,000	1,101,000,000

Accounts Payable & Accrued Expenses	2,847,000,000	2,764,000,000
Current Debt	682,000,000	914,000,000
Current Debt and Capital Leases	682,000,000	914,000,000
Other Current Liabilities	934,000,000	954,000,000
Current Liabilities	4,463,000,000	4,632,000,000
Long-Term Obligations	3,529,000,000	3,292,000,000
Deferred LT Liability		
Charges	185,000,000	244,000,000
Pensions & OPEB	728,000,000	695,000,000
Other LT Liabilities	1,152,000,000	1,022,000,000
Minorities (BS)	104,000,000	95,000,000
LT Liabilities	5,698,000,000	5,348,000,000
Total Liabilities	10,161,000,000	9,980,000,000
Net Assets	11,551,000,000	10,802,000,000
Common Share Capital	142,000,000	146,000,000
Retained Earnings	12,947,000,000	12,832,000,000
Accum Other Comp Inc	(158,000,000)	(495,000,000)
Treasury Stock	1,380,000,000	1,681,000,000
For Curr Trans (BS)	75,000,000	(177,000,000)
Other Equity	(75,000,000)	177,000,000
Shareholders' Equity	11,551,000,000	10,802,000,000
Total Liabilities & Stockholders' Equity	21,712,000,000	20,782,000,000
Net Current Assets	3,429,000,000	2,636,000,000
Total Assets Less Current Liabilities	17,249,000,000	16,150,000,000
Shares Outstanding	311,982,539	318,081,241

Recent Dividends:

1. TE Connectivity Ltd common.

ExDate	Amt	Declared	Record	Payable
02/20/2020	0.46	02/04/2020	02/21/2020	03/06/2020
05/21/2020	0.48	05/05/2020	05/22/2020	06/05/2020
08/20/2020	0.48	08/04/2020	08/21/2020	09/04/2020
11/19/2020	0.48	11/03/2020	11/20/2020	12/04/2020
02/18/2021	0.48	02/02/2021	02/19/2021	03/05/2021
05/20/2021	0.50	03/10/2021	05/21/2021	06/04/2021
08/19/2021	0.50	03/10/2021	08/20/2021	09/03/2021
11/18/2021	0.50	03/10/2021	11/19/2021	12/03/2021
02/17/2022	0.50	03/10/2021	02/18/2022	03/04/2022
05/19/2022	0.56	03/09/2022	05/20/2022	06/03/2022
08/18/2022	0.56	03/09/2022	08/19/2022	09/02/2022
11/17/2022	0.56	03/09/2022	11/18/2022	12/02/2022
02/16/2023	0.56	03/09/2022	02/17/2023	03/03/2023
05/18/2023	0.59	03/15/2023	05/19/2023	06/02/2023
08/17/2023	0.59	03/15/2023	08/18/2023	09/01/2023

Annual Dividends:

1. TE Connectivity Ltd common.

2020	1.90	2021	1.98	2022	2.18
2023	1.74				

TILL CAPITAL CORP

Annual Report Standardized Income Statement, Years Ended Dec. 31 (\$000):

	2022	2021	2020 (revised)
Net Investment Income	70	(7)	(409)
Revenue	(1,719)	6,761	(450)
General & Admin Expenses	760	883	574
EBT Continuing	(3,626)	4,723	(1,968)
Taxation (current)	1,684	3	(21)
Taxation (deferred)	(630)	1,203	...
Taxation	1,158	1,469	385
EAT Continuing	(4,784)	3,254	(2,353)
Min Ints	(617)	29	46
Disc Ops	(534)	(3)	747
Net Income	(4,205)	4,805	(1,560)
EPS - Basic - Cont	(1.32)	1.51	(0.49)
EPS - Primary	(1.32)	1.51	(0.49)
EPS - Diluted - Cont	(1.32)	1.51	(0.49)
EPS - Diluted	(1.32)	1.51	(0.49)
Shares (primary)	3,191	3,191	3,191
Shares (diluted)	3,191	3,191	3,191
Taxation (Cumulative)	385
Min Ints (Cumulative)	46

EPS - Primary (Cumulative)	(0.49)
EPS - Diluted (Cumulative)	(0.49)

Standardized Balance Sheet, Years Ended Dec. 31 (\$000):

	2022	2021
Cash & Equivalents	668	611
Assets Held for Sale (ST)	57,021	56,655
Other Assets	64,189	70,283
Total Assets	64,857	70,894
Accrued Exps	26	25
Minorities (BS)	940	156
Other Liabilities	47,200	45,704
Total Liabilities	47,227	45,729
Net Assets	17,630	25,166
Common Share Capital	3	3
Share Premium	41,041	40,957
Retained Earnings	(19,818)	(15,613)
Accum Other Comp Inc	(3,596)	(181)
Other Equity	0	0
Shareholders' Equity	17,630	25,166
Total Liabilities & Stockholders' Equity	64,857	70,894
Shares Outstanding	3,191	3,191

Recent Dividends:

1. Till Capital Corp restricted voting common.

No dividends paid.

2. Till Capital Corp common.

No dividends paid.

Annual Dividends:

1. Till Capital Corp restricted voting common.

No dividends paid.

2. Till Capital Corp common.

No dividends paid.

UCLOUDLINK GROUP INC

Annual Report Standardized Income Statement, Years Ended Dec. 31 (\$000):

	2022	2021	2020
Sales	71,461	73,824	89,569
Revenue	71,461	73,824	89,569
Direct Expenses	38,927	51,990	61,264
Gross Profit	32,534	21,834	28,305
SG&A	29,031	42,171	72,482
R&D (OpEx)	8,430	13,697	26,359
Other OpEx	14,480	11,970	(7,179)
Indirect Expenses	51,941	67,838	91,662
Total Operating Expenses	90,868	119,828	152,926
Operating Income	(19,407)	(46,004)	(63,357)
Non-Op Net Interest Income	(423)	(174)	(248)
Non-Op Gains	215	94	375
Other Non-Op	(149)	0	0
Non-Op Income	(357)	(80)	127
EBT Continuing	(19,764)	(46,084)	(63,230)
Taxation	161	244	185
Equity Earns	72	287	...
Extraord	0	0	0
Acc Changes	0	0	0
Net Income	(19,853)	(46,041)	(63,415)
Pref Divs & Similar	0	0	(1,293)
Net Income to Common	(19,853)	(46,041)	(64,708)
EPS - Basic - Cont	(0.06)	(0.16)	(0.25)
EPS - Primary	(0.06)	(0.16)	(0.25)
EPS - Diluted - Cont	(0.06)	(0.16)	(0.25)
EPS - Diluted	(0.06)	(0.16)	(0.25)
Shares (primary)	312,485	285,979	259,852
Shares (diluted)	312,485	285,979	259,852

Standardized Balance Sheet, Years Ended Dec. 31 (\$000):

	2022	2021
Cash & Equivalents	14,921	7,868
Short Term Investments	11,690	12,587
Cash, Equivs & STI	26,611	20,455

Receivables	5,961	14,923	Acc Changes	0	0	0
Raw Materials	1,971	4,395	Net Income	(148)	(107)	(149)
Finished Goods	2,401	2,390	Pref Divs &			
Inventories - Other	(1,496)	(1,304)	Similar	0	0	0
Inventories	3,624	6,133	Net Income to			
Related Parties (ST			Common	(148)	(107)	(149)
Asset)	698	1,153	EPS - Basic - Cont	0	0	0
Other Current Assets	4,452	6,421	EPS - Primary	0	0	0
Current Assets	41,346	49,085	EPS - Diluted -			
Gross PPE	11,795	13,960	Cont	0	0	0
Accumulated Depreciation	10,614	12,164	EPS - Diluted	0	0	0
Net PPE	1,181	1,796	Shares (primary)	109,545	108,592	107,005
LT Investments	1,711	12,058	Shares (diluted)	109,545	108,592	107,005
Intangibles	802	1,009				
LT Receivables	688	1,310				
Other LT Assets	206	1,867				
LT Assets	4,588	18,040				
Total Assets	45,934	67,125				
Accounts Payable	6,832	12,986				
Accrued Exps	24,014	27,580				
Accounts Payable &						
Accrued Expenses	30,846	40,566				
Current Debt	2,876	3,177				
Current Debt and Capital						
Leases	2,876	3,177				
Related Parties (ST Liab)	1,481	1,453				
Other Current Liabilities	1,236	1,575				
Current Liabilities	36,439	46,771				
Other LT Liabilities	204	262				
Minorities (BS)	0	0				
LT Liabilities	204	262				
Total Liabilities	36,643	47,033				
Net Assets	9,291	20,092				
Common Share Capital	18	14				
Share Premium	236,774	230,048				
Retained Earnings	(229,377)	(209,524)				
Accum Other Comp Inc	1,876	(446)				
Other Equity	0	0				
Shareholders' Equity	9,291	20,092				
Total Liabilities &						
Stockholders' Equity	45,934	67,125				
Net Current Assets	4,907	2,314				
Total Assets Less Current						
Liabilities	9,495	20,354				
Shares Outstanding	368,759	287,048				

Recent Dividends:**1. uCloudlink Group Inc class A ordinary.**

No dividends paid.

2. uCloudlink Group Inc class B ordinary.

No dividends paid.

3. uCloudlink Group Inc American Depositary Receipt.

No dividends paid.

Annual Dividends:**1. uCloudlink Group Inc class A ordinary.**

No dividends paid.

2. uCloudlink Group Inc class B ordinary.

No dividends paid.

3. uCloudlink Group Inc American Depositary Receipt.

No dividends paid.

UMEWORLD LTD**Annual Report****Standardized Income Statement, Years Ended Sept. 30****(\$000):**

	2022	2021	2020
			(revised)
Other Revenue	0	3	0
Revenue	0	3	0
Direct Expenses	1	20	0
Gross Profit	(1)	(17)	0
SG&A	86	87	135
Other OpEx	0	0	0
Indirect Expenses	86	87	135
Total Operating			
Expenses	87	106	135
Operating Income	(86)	(104)	(135)
Non-Op Net Interest			
Income	...	0	0
Other Non-Op	...	(4)	(14)
Non-Op Income	3	(4)	(14)
EBT Continuing	(84)	(107)	(149)
Disc Ops	(64)
Extraord	0	0	0

Standardized Balance Sheet, Years Ended Sept. 30 (\$000):

	2022	2021
Cash	2	8
Cash & Equivalents	2	8
Cash, Equivs & STI	2	8
Receivables	0	...
Inventories	12	...
Prepayments (ST)	...	27
Other Current Assets	14	2
Current Assets	28	37
Net PPE	...	19
Other LT Assets	...	0
LT Assets	...	19
Total Assets	28	56
Accounts Payable	22	23
Accounts Payable &		
Accrued Expenses	172	235
Current Debt	0	0
Related Parties (ST Liab)	210	28
Other Current Liabilities	0	0
Current Liabilities	382	263
Minorities (BS)	0	0
Total Liabilities	382	263
Net Assets	(354)	(207)
Common Share Capital	11	11
Share Premium	30,657	30,657
Retained Earnings	(31,141)	(30,993)
Accum Other Comp Inc	118	118
Other Equity	0	0
Shareholders' Equity	(354)	(207)
Total Liabilities &		
Stockholders' Equity	28	56
Net Current Assets	(354)	(226)
Total Assets Less Current		
Liabilities	(354)	(207)
Shares Outstanding	109,545	109,545

Recent Dividends:**1. UMeWorld Ltd ordinary.**

No dividends paid.

Annual Dividends:**1. UMeWorld Ltd ordinary.**

No dividends paid.

UMEWORLD LTD**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, J&S Associate PLT, as it appeared in the 2022 20-F: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheet of UMeWorld Limited and its subsidiaries (collectively, the "Company") as of September 30, 2022 and 2021, and the related consolidated statements of operations and comprehensive loss, changes in stockholders' deficit and cash flows for each of the years in the three-year period ended September 30, 2022, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2022, and the results of its operations and its cash flows for each of the years in the three-year period ended September 30, 2022 in conformity with accounting principles generally accepted in the United States of America. Substantial Doubt about the Company's Ability to Continue as a Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in note 1 to the financial statements, the Company has suffered from an accumulated deficit of \$31,140,663 as at September 30, 2022. These factors create uncertainty as to the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described

in note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis for Opinion These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

*

MERGENT INTERNATIONAL News Reports 0278-3517 is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the INTERNATIONAL Manual and provide periodic updates. Send address changes to MERGENT INTERNATIONAL, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2023 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.